AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Schrödinger vs BenevolentAI

Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.

VS
Schrödinger official logo and brand icon

Schrödinger

Enterprise
Visit WebsiteFull Review
BenevolentAI official logo and brand icon

BenevolentAI

Enterprise
Visit WebsiteFull Review

Verdict by Category

AI content generation failed. Refresh the page to try again.
View Schrödinger View BenevolentAI
Feature & Spec Matrix

Detailed Comparison24 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
Schrödinger
Schrödinger
BenevolentAI
BenevolentAI
Pricing Model
EnterprisePhysics-based molecular modeling & drug discovery suite — Academic site licenses & commercial enterprise quotes on sales consultation
EnterpriseBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing. Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development. Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
Academic licensing available at reduced rates; commercial pricing via sales team
No free access — enterprise pharma partnerships and platform licensing via sales team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical scientists and computational chemists needing physics-based molecular simulation for drug discovery, lead optimization, and ADMET prediction
Pharmaceutical companies and researchers needing AI-powered knowledge mining for novel drug target identification and disease hypothesis generation in complex diseases
Enterprise & Scalability
Difference
NASDAQ listed (SDGR), enterprise software licensing with volume pricing, cloud-hosted subscriptions, strategic research collaborations with BMS, Sanofi, and Takeda, dedicated scientific support teams, and academic/government licensing programs
Euronext Amsterdam listed (AMS: BAI), $1.9B total raised, in-house wet lab facilities in Cambridge UK, strategic collaborations with AstraZeneca and Merck, HIPAA/GDPR compliant data practices, enterprise licensing for knowledge exploration tools
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Physics-based molecular simulation: Maestro, Glide, Jaguar, Prime, and FEP+ for drug and materials discovery
Supported
Supported
Bunsen AI co-scientist (July 2026) for hypothesis generation, experiment design, and molecular insight
Supported
Supported
FEP+ for industry-leading binding affinity prediction in lead optimization
Difference
Schrödinger Advantage
Not listed
Structure-based drug design, ADMET prediction, and quantum chemistry in one platform
Difference
Schrödinger Advantage
Not listed
Cloud-hosted software subscriptions with 10-15% ACV growth target for 2026
Difference
Schrödinger Advantage
Not listed
Drug discovery pipeline with BMS, Sanofi, and Takeda — FY26 guidance raised to $65-75M
Supported
Supported
Materials science applications: battery design, semiconductors, and specialty chemicals
Difference
Schrödinger Advantage
Not listed
$255.87M revenue in 2025 with 23% growth — NASDAQ listed (SDGR)
Difference
Schrödinger Advantage
Not listed
500+ enterprise customers including top 20 global pharma companies
Difference
Schrödinger Advantage
Not listed
Founded 1990 by Professor Richard Friesner — 34+ years of computational chemistry leadership
Difference
Schrödinger Advantage
Not listed
Benevolent Platform — AI knowledge graph integrating scientific literature, databases, and experimental data
Difference
Not listed
BenevolentAI Advantage
In-house wet lab facilities in Cambridge UK for AI hypothesis validation
Difference
Not listed
BenevolentAI Advantage
Clinical pipeline: BEN-8744 (Phase 1, ulcerative colitis), BEN-28010 (preclinical, glioblastoma), BEN-34712 (preclinical, ALS)
Difference
Not listed
BenevolentAI Advantage
Integrated AI + wet lab model: AI generates hypotheses, scientists validate in physical experiments
Difference
Not listed
BenevolentAI Advantage
Multi-disease focus: oncology, rare disease, fibrosis, CNS, immunology, and cardiovascular
Difference
Not listed
BenevolentAI Advantage
Listed on Euronext Amsterdam (AMS: BAI) — $1.9B total raised since founding in 2013
Difference
Not listed
BenevolentAI Advantage
Offices in London HQ, Cambridge wet labs, and New York
Difference
Not listed
BenevolentAI Advantage
Schrödinger icon

Schrödinger Pros & Cons

Pros

  • 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
  • Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
  • FEP+ delivers industry-leading accuracy in binding affinity prediction
  • NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
  • 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
  • Materials science applications extend reach to battery, semiconductor, and chemical sectors
  • Cloud-hosted subscriptions eliminate on-premise infrastructure burden

Cons

  • Software is expensive — enterprise pricing puts it out of reach for smaller labs
  • Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
  • Drug discovery segment revenue is milestone-dependent and lumpy
  • Platform learning curve is steep without computational chemistry background
  • Competition from newer, purely AI-native platforms is intensifying
BenevolentAI icon

BenevolentAI Pros & Cons

Pros

  • Fully integrated AI + wet lab model — unique among AI drug discovery platforms
  • AstraZeneca and Merck partnerships validate the platform's target identification quality
  • In-house wet labs in Cambridge close the loop between AI prediction and biology
  • Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
  • Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
  • Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
  • Knowledge exploration tools can be licensed separately from drug pipeline

Cons

  • Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
  • Clinical pipeline still in early stages — no approved drugs yet
  • Smaller than competitors like Recursion in terms of funding and team size
  • Revenue dependent on collaboration milestones — lumpy and uncertain
  • Wet-lab operations add cost complexity vs. pure software drug discovery peers
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Schrödinger vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Schrödinger and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
BenevolentAI vs Freed AI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between BenevolentAI and Freed AI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Infermedica vs BenevolentAI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Infermedica and BenevolentAI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Google NotebookLM vs Obsidian Comparison Battle Card - Features, Pricing & Review in AI Research Synthesis & Personal Knowledge Management
Direct head-to-head AI tool comparison between Google NotebookLM and Obsidian in AI Research Synthesis & Personal Knowledge Management featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Research Synthesis & Personal Knowledge ManagementCompare